Biotech Startup Telum Therapeutics Raises €18 Mn in Series A Round

The round was led by the AMR Action Fund, with participation from new investor Inveready and continued support from existing investors Invivo Partners, CDTI (through SICC Innvierte), Clave Capital, and Sodena.

Read Also- Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer

The company will use the funding to advance its lead drug program for treating hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).

Dr. Henry Skinner, Chief Executive Officer of the AMR Action Fund, commented: “Acinetobacter baumannii is one of the most formidable bacterial threats in modern medicine. It is clinically challenging, often resistant to first-line therapies, and a pathogen for which progress has been slow and di\icult to achieve. We are encouraged by Telum’s novel approach and pleased to support the team as they work to bring forward a new treatment option for patients with life-threatening infections.”

Dr. Subhendu Basu, Chief Executive Officer of Telum Therapeutics, said: “We are delighted to welcome AMR Action Fund and Inveready as new investors in Telum. AMR Action Fund’s dedicated focus and deep expertise in antimicrobial resistance, together with the continued support of Invivo Partners, Clave Capital, CDTI-Innvierte, and Sodena, reinforces our confidence in the potential of the APEX® platform to generate a new class of antimicrobial therapies for di\icult-to-treat infections. This financing provides a clear path to complete Phase 1 development of our lead program targeting Acinetobacter baumannii HABP/VABP, while also enabling us to advance our broader pipeline addressing both Gram-negative and Gram-positive pathogens.”

Dr. Laura Rodríguez, Partner at Invivo and Board member at Telum, commented: “Having supported Telum since its earliest stages, we are delighted to welcome AMR Action Fund as lead investor in this financing. Their participation is a strong validation of the progress achieved by the Company, the quality of its science, and the commitment of the team to tackling antimicrobial resistance. We believe this round marks a defining milestone in Telum’s evolution, reinforcing its position within the global antimicrobial innovation ecosystem and equipping the Company with the resources, expertise and support needed to advance into the clinic.”

Dr. Roberto Díez, Founder and Chief Operating Officer of Telum Therapeutics, added: “Telum was founded with the vision of developing a new generation of antimicrobial therapies capable of combating some of the world’s most dangerous drug-resistant pathogens. This financing marks an important milestone for the Company and reflects the strength of our scientific platform, the progress of our lead program, and the growing recognition that innovative solutions are urgently needed to address the global threat of antimicrobial resistance.”

Founded in 2019, Telum Therapeutics is a Spain-based biotechnology company that develops new treatments for serious bacterial infections, especially those caused by drug-resistant bacteria.

The company uses its APEX® platform to discover and develop protein-based antimicrobial medicines that target both Gram-negative and Gram-positive bacteria.

Its lead drug program is focused on treating hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii.